The first Non-Antipsychotic Drug to Treat Agitation in Dementia, by Axsome Therapeutics, has been approved by the FDA, and we are so proud to have been a part of contributing to this groundbreaking approval. Premier Clinical Research Institute was one of the contributing research sites that provided valuable data to the clinical trials that eventually led to the FDA's approval of the medication, Auvelity for this condition. Auvelity was already FDA-approved as an oral antidep